Journal
OSTEOPOROSIS INTERNATIONAL
Volume 23, Issue 3, Pages 1141-1150Publisher
SPRINGER LONDON LTD
DOI: 10.1007/s00198-011-1742-7
Keywords
Alendronate; Mouse; oim/oim; Osteogenesis imperfecta; RANK/RANKL; RANK-Fc
Categories
Funding
- Osteogenesis Foundation
- Amgen
- NIH [AR48337, AR046121]
Ask authors/readers for more resources
We report a direct comparison of receptor activator of nuclear factor kappa B ligand (RANKL) inhibition (RANK-Fc) with bisphosphonate treatment (alendronate, ALN) from infancy through early adulthood in a mouse model of osteogenesis imperfecta. Both ALN and RANK-Fc decreased fracture incidence to the same degree with increases in metaphyseal bone volume via increased number of thinner trabeculae. The potential therapeutic benefit of RANKL inhibitors in osteogenesis imperfecta (OI) is under investigation. We report a direct comparison of RANKL inhibition (RANK-Fc) with bisphosphonate treatment (ALN) from infancy through early adulthood in a model of OI, the oim/oim mouse. Two-week-old oim/oim, oim/+, and wildtype (+/+) mice were treated with RANK-Fc 1.5 mg/kg twice per week, ALN 0.21 mg/kg/week or saline (n = 12-20 per group) for 12 weeks. ALN and RANK-Fc both decreased fracture incidence (9.0 +/- 3.0 saline 4.4 +/- 2.7 ALN, 4.3 +/- 3.0 RANK-Fc fractures per mouse). Serum TRACP-5b activity decreased to 65% after 1 month in all treated mice, but increased sacrifice with RANK-Fc to 130-200% at sacrifice. Metaphyseal density was significantly increased with ALN in +/+ and oim/oim mice (p < 0.05) and tended to increase with RANK-Fc in +/+ mice. No changes in oim/oim femur biomechanical parameters occurred with treatment. Both ALN and RANK-Fc significantly increased trabecular number (3.73 +/- 0.77 1/mm for oim/oim saline vs 7.93 +/- 0.67 ALN and 7.34 +/- 1.38 RANK-Fc) and decreased trabecular thickness (0.045 mm +/- 0.003 for oim/oim saline vs 0.034 +/- 0.003 ALN and 0.032 +/- 0.002 RANK-Fc) and separation in all genotypes (0.28 +/- 0.08 mm for oim/oim saline vs 0.12 +/- 0.010 ALN and 13 +/- 0.03 RANK-Fc)., with significant increase in bone volume fraction (BVF) with ALN, and a trend towards increased BVF in RANK-Fc. Treatment of oim/oim mice with either a bisphosphonate or a RANK-Fc causes similar decreases in fracture incidence with increases in metaphyseal bone volume via increased number of thinner trabeculae.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available